Related Experiment Video
Updated: May 24, 2025
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Prognostic Significance of Homocysteine Levels in Patients with ST-Segment Elevation Myocardial Infarction Undergoing
Qianfeng Xiong1, Shaoyong Chen1, Junke Luo2
1Department of Cardiology, Fengcheng People's Hospital, The Affiliated Fengcheng Hospital of Yichun University, 331100 Fengcheng, Jiangxi, China.
Insights
Elevated homocysteine (Hcy) levels predict major adverse cardiac events (MACE) in ST-segment elevation myocardial infarction (STEMI) patients after primary percutaneous coronary intervention (PCI). Higher Hcy levels indicate a worse prognosis, underscoring Hcy
Area of Science:
- Cardiology
- Biochemistry
- Clinical Medicine
Background:
- Elevated homocysteine (Hcy) is linked to adverse outcomes in acute coronary syndrome.
- This study investigates Hcy's predictive role in ST-segment elevation myocardial infarction (STEMI).
Purpose of the Study:
- To assess the predictive value of elevated Hcy for major adverse cardiac events (MACE) in STEMI patients undergoing primary percutaneous coronary intervention (PCI).
Main Methods:
- Retrospective cohort study of 183 STEMI patients undergoing primary PCI.
- Hcy levels measured within 24 hours; elevated group defined as ≥12 μmol/L.
- Propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) used for bias reduction.
Main Results:
- Elevated Hcy was associated with a significantly higher incidence of MACE (30.1% overall).
- Adjusted analyses (PSM, IPTW) confirmed elevated Hcy as a predictor of MACE (HRs ranging from 2.995 to 3.2).
- Multivariate Cox regression showed elevated Hcy consistently predicted worse prognosis (HRs 1.052-1.089).
Conclusions:
- Elevated plasma Hcy levels (≥12 μmol/L) are associated with worse outcomes in STEMI patients post-primary PCI.
- Hcy may serve as a valuable prognostic marker for identifying high-risk patients in this population.
Background:
Elevated homocysteine (Hcy) levels have been linked to poorer outcomes in acute coronary syndrome. This study aimed to assess the predictive value of elevated Hcy levels for major adverse cardiac events (MACE) in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI).
Methods:
This retrospective cohort study included 183 STEMI patients who underwent primary PCI at a tertiary university hospital in southern China from January 2020 to December 2021. Laboratory values, including Hcy levels, were obtained within 24 hours of admission. Patients were categorized into elevated and normal Hcy groups using a threshold of 12 μmol/L. The study outcome was the occurrence of 6-point MACE, defined as cardiac death, nonfatal myocardial infarction, stroke, ischemia-driven revascularization (PCI or coronary artery bypass grafting), heart failure and all-cause death. Survival analyses were conducted using Kaplan-Meier and Cox proportional hazard methods. Propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) approaches were employed to minimize bias.
Results:
The mean age of the patients was 64.8 years, with 76.0% being male. After adjusting with PSM or IPTW, covariate imbalances between the two groups were corrected. Over a median follow-up period of 25.8 months, 55 MACE events occurred, resulting in an event rate of 30.1%. Patients with elevated Hcy levels had a higher incidence of MACE in both unadjusted (hazard ratio [HR] = 2.778; 95% confidence interval [CI]: 1.591-4.850; p < 0.001) and adjusted analyses (PSM: HR = 2.995; 95% CI: 1.397-6.423, p = 0.005; IPTW: HR = 3.2; 95% CI: 1.631-6.280, p < 0.001). Multivariate Cox regression further confirmed that elevated Hcy levels were associated with a worse prognosis across the entire cohort (HR = 1.062, 95% CI: 1.029-1.097, p < 0.001), PSM cohort (HR = 1.089, 95% CI: 1.036-1.145, p < 0.001), and IPTW cohort (HR = 1.052, 95% CI: 1.020-1.086, p = 0.001).
Conclusions:
Elevated plasma levels of Hcy (≥12 μmol/L) are associated with worse outcomes in STEMI patients undergoing primary PCI, highlighting the potential role of Hcy as a prognostic marker in this population.
More Related Videos
Related Concept Videos
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...